Brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce $13.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $11.00 million and the highest is $14.80 million. Theravance Biopharma reported sales of $12.84 million in the same quarter last year, which indicates a positive year-over-year growth rate of 1.9%. The business is scheduled to issue its next earnings results on Tuesday, November 5th.
On average, analysts expect that Theravance Biopharma will report full year sales of $52.83 million for the current fiscal year, with estimates ranging from $45.78 million to $57.70 million. For the next fiscal year, analysts expect that the company will report sales of $97.99 million, with estimates ranging from $74.18 million to $129.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.50. Theravance Biopharma had a negative net margin of 369.67% and a negative return on equity of 2,631.71%. The business had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $13.92 million.
A number of research analysts have commented on TBPH shares. Cantor Fitzgerald reiterated a “buy” rating and set a $55.00 price target on shares of Theravance Biopharma in a research report on Friday, April 12th. Piper Jaffray Companies set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday. Finally, BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma currently has a consensus rating of “Buy” and a consensus target price of $44.25.
In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $20.46, for a total transaction of $81,840.00. Following the transaction, the director now directly owns 30,244 shares in the company, valued at $618,792.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.60% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of TBPH. Norges Bank bought a new position in shares of Theravance Biopharma in the fourth quarter worth approximately $22,422,000. Fosun International Ltd bought a new position in shares of Theravance Biopharma in the first quarter worth approximately $2,386,000. Geode Capital Management LLC grew its holdings in shares of Theravance Biopharma by 10.2% in the fourth quarter. Geode Capital Management LLC now owns 497,224 shares of the biopharmaceutical company’s stock worth $12,723,000 after purchasing an additional 46,003 shares during the last quarter. Tibra Equities Europe Ltd bought a new position in shares of Theravance Biopharma in the first quarter worth approximately $660,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Theravance Biopharma by 46.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 75,034 shares of the biopharmaceutical company’s stock worth $1,920,000 after purchasing an additional 23,885 shares during the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.
NASDAQ TBPH traded down $0.50 on Monday, reaching $20.66. 320,049 shares of the company’s stock traded hands, compared to its average volume of 231,457. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $35.48. The stock has a 50-day moving average price of $17.48. The firm has a market cap of $1.17 billion, a PE ratio of -5.18 and a beta of 1.74.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Further Reading: Why is momentum important to successful trading?
Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.